[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640261":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":58,"centralContacts":62,"locations":69,"responsibleParty":88,"collaborators":67,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":67,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":67,"studyType":104,"phases":105,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":121,"whyStopped":67,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14,19,24,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: Low-Dose EYED-002","EXPERIMENTAL","N=5 participants with open-angle glaucoma. Low-dose topical insulin (EYED-002), administered as one drop to the study eye once daily in-clinic for 5 consecutive days. Open-label.",[13],"Drug: EYED-002 Low Dose (721 U\u002FmL topical insulin)",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2: High-Dose EYED-002","N=5 participants with open-angle glaucoma. High-dose topical insulin (EYED-002), administered as one drop to the study eye once daily in-clinic for 5 consecutive days.",[18],"Drug: EYED-002 High Dose (1442 U\u002FmL topical insulin)",{"label":20,"type":10,"description":21,"interventionNames":22},"Group 3: Active EYED-002 (Randomized)","N=40 participants randomized to active EYED-002 at the highest tolerated dose from Groups 1 or 2, administered once daily at home for 12 months. Double -masked.",[23],"Drug: EYED-002 (highest tolerated dose, 12-month)",{"label":25,"type":26,"description":27,"interventionNames":28},"Group 3: Vehicle Placebo (Randomized)","PLACEBO_COMPARATOR","N=20 participants randomized to vehicle-only placebo, administered once daily at home for 12 months. double-masked. Eligible participants may roll over to open-label active EYED-002 for an additional 12 months after Month 12.",[29],"Drug: Vehicle Placebo",{"label":31,"type":10,"description":32,"interventionNames":33},"Group 4: Open-Label Access","N=20 participants ineligible for randomization due to glaucoma severity. Receive highest tolerated dose of EYED-002 once daily for 12 months in an open-label access arm.",[23],[35,42,47,52],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","EYED-002 Low Dose (721 U\u002FmL topical insulin)","Sterile, preservative-free suspension of Human Insulin USP. One drop to study eye for duration of study group.",[9],[41],"Topical Sterile Human Insulin",{"type":36,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"EYED-002 High Dose (1442 U\u002FmL topical insulin)","Sterile, preservative-free suspension of Human Insulin USP. One drop to study eye once daily in-clinic for duration of study group.",[15],[41],{"type":36,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"EYED-002 (highest tolerated dose, 12-month)","Highest tolerated dose of EYED-002 (721 U\u002FmL or 1442 U\u002FmL, determined from Groups 1 and 2 safety review). Once daily at home for 12 months in single-use vials, dispensed at quarterly visits.",[20,31],[41],{"type":36,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Vehicle Placebo","Vehicle-only formulation without active insulin. Single-use vials identical in appearance to active EYED-002. Once daily at home for 12 months.",[25],[57],"Placebo eye drop",[59],{"name":60,"affiliation":5,"role":61},"Jeffrey L Goldberg, MD PhD","PRINCIPAL_INVESTIGATOR",[63],{"name":64,"role":65,"phone":66,"phoneExt":67,"email":68},"Study Team","CONTACT","650-497-5942",null,"glaucomatrials@stanford.edu",[70],{"facility":71,"status":67,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"Byers Eye Institute at Stanford University","Palo Alto","California","94303","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-122.14302,37.44188,{"lat":81,"lon":80},[84,86],{"name":64,"role":65,"phone":85,"phoneExt":67,"email":68},"6504975942",{"name":87,"role":61,"phone":67,"phoneExt":67,"email":67},"Jeffrey Goldberg, MD PhD",{"type":61,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":67,"oldOrganization":67},"Jeffrey L Goldberg","Professor and Chair of Ophthalmology","100640261","phase-1-topical-insulin-for-glaucoma-ting2-100640261",false,"NCT07619482","Topical Insulin for Glaucoma (TING2)","A Phase 1\u002F2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma","Limited Inclusion Criteria - All Groups:\n\n* Provide written informed consent approved by the appropriate ethics committee\n* Age 18 years or older\n* Understand study procedures and have the ability and willingness to abide by all procedures during the study\n* Capable of providing informed consent\n* Diagnosis of glaucoma\n* Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and\u002For visual field will be selected\n\nLimited Exclusion Criteria - All Groups:\n\n* Pregnant or breastfeeding\n* Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.)\n* Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus\n* Inability to perform reliable visual field testing\n* Unable to provide informed consent\n* Unable to complete the tests and follow-ups required by the study","ALL","18 Years","90 Years",{"count":102,"type":103},90,"ESTIMATED","INTERVENTIONAL",[106,107],"PHASE1","PHASE2","This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1\u002F2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.",[110,111,112,113,114],"Open Angle Glaucoma","Primary Open Angle Glaucoma","Low Tension Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[116,117,118,119,120],"glaucoma","neuroprotection","topical insulin","retinal ganglion cell","EYED-002","NOT_YET_RECRUITING","2026-05-26",{"date":124,"type":125},"2026-06-02","ACTUAL",{"date":127,"type":103},"2026-06",{"date":129,"type":103},"2029-10",{"name":5,"class":6},1]